MAPT and Alzheimer disease: For example, in two different transgenic mouse models of AD, the pre-stress application of a CRF receptor Type 1 (CRFr1) antagonist prevented the stress-induced accumulation of Aβ, tau aggregation, neurodegeneration, and memory impairments (213).